Julia Arndt, M.Sc.
Phone: +49 (0)711 - 2 29 87 33
Fax: +49 (0)711 - 2 29 87 50
send an Email
J. Harenberg (1), C. Weiss (2)
(1) Department of Clinical Pharmacology, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany; (2) Department of Biometry and Statistics, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
Atrial fibrillation, total hip replacement, oral anticoagulants, rivaroxaban, total knee replacement, dabigatran, Apixaban, prophylaxis of thromboembolism
To compare the efficacy and safety of the new oral anticoagulants (NOAC), ideally head-to-head clinical trials should be performed. Given the expense of such an undertaking, it is highly unlikely that such a comparison would be performed. Therefore, there is a need for an unbiased comparative assessment of the benefits and risks of the NOACs, based on the available trial data. Indirect or mixed treatment comparisons may be an useful tool to overcome these limitations also known as network meta-analysis (NMA). The aim of this paper is to give an overview on published NMAs for dabigatran, rivaroxaban and apixaban, each assessed against warfarin in patients with atrial fibrillation, and against enoxaparin in patients undergoing total knee and total hip replacement surgery, in order to obtain insights into the comparability of the adopted methodological techniques.
Additive value of indirect comparisons (network meta-analyses)
J. Harenberg (1), C. Weiss (2), S. Marx (1), S. Zolfaghari (1)
Phlebologie 2013 42 3: 139-148
Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation
An indirect comparison analysis
F. Skjøth (1, 2), T. B. Larsen (1, 2), L. H. Rasmussen (1, 2), G. Y. H. Lip (1, 3)
Thromb Haemost 2014 111 5: 981-988
Ready to be replaced?
J. Steffel (1), T. F. Luscher (1)
Hämostaseologie 2012 32 4: 249-257